ADMA Biologics, Inc.

The forensic scores point in different directions, and a careful reader should weigh them together. The Beneish M-Score of 0.020 falls in the elevated manipulation-risk zone. This is a screening model that compares ratios across periods to flag patterns sometimes seen in misstated financials, so an elevated reading calls for a closer read of the filings rather than a conclusion that anything improper occurred. The Altman Z-Score of 6.18 is in the safe zone, which under that model indicates low near-term financial-distress risk. The 2024 operating cash flow to net income ratio of 0.60 means cash generation trailed reported profit; the gap is consistent with a large non-cash tax benefit, although the excerpt does not quantify it. Readers may want to look at the risk-factor and forward-looking sections, which name dependence on third-party suppliers and vendors, delays in cGMP release testing by third-party vendors, plasma supply availability, and competition for Nabi-HB. The 2025 voluntary withdrawal of three BIVIGAM lots reduced revenue by $4.0 million through customer credits, which management says it believes is resolved. Debt activity is also worth tracking. The company repaid all obligations under the Ares Credit Facility, recording a $2.2 million loss on extinguishment in the third quarter of 2025 and $3.3 million for the nine months, while the JPM Term Loan Facility remains outstanding and a $2.34 million current portion of long-term debt appears on the September 30, 2025 balance sheet. Research spending on the SG-001 program remains small, at $1.5 million in the quarter.

Catalyst.According to the MD&A, growth is driven mainly by higher sales volume of ASCENIV, which management attributes to increasing physician, payer and patient acceptance. Revenues for the nine months ended September 30, 2025 were $371.01 million, up from $308.91 million, an increase of about 20%. Third-quarter revenues were $134.2 million versus $119.8 million, and third-quarter gross margin rose to 56.3% from 49.8%, which management ties to product mix and manufacturing efficiencies. Full-year 2024 revenue was $426.45 million, up 65.1% from $258.21 million in 2023.

Hidden risk.The most easily missed tension is between reported profit and cash and balance-sheet movement. In 2024, operating cash flow was $118.67 million against net income of $197.67 million, a ratio of 0.60, and the MD&A notes the company released its valuation allowance on deferred tax assets in December 2024. Accounts receivable rose from $49.99 million at December 31, 2024 to $137.67 million at September 30, 2025, while cash fell from $103.15 million to $61.39 million. The Beneish M-Score of 0.020 sits in the elevated manipulation-risk zone, which is a screening flag rather than proof of manipulation.